Tapentadol withdrawal, a newer trend in opioid overuse in Nepal: A case report

  • Hemant Chand Department of Emergency Medicine, Nova Hospital, Nepal
  • Om Prakash Bhatta Department of Emergency Medicine, Nova Hospital, Nepal
  • Sabita Chand Department of Emergency Medicine, Nova Hospital, Nepal
  • Neha Dangol Department of Emergency Medicine, Nova Hospital, Nepal
  • Sachin Awasthi Department of Emergency Medicine, Yashoda Hospital, Nepal
  • Ram Chandra Poudel Department of Internal Medicine, Nova Hospital, Nepal
  • Ram Prasad Lamichhane Department of Psychiatry, Nova Hospital, Nepal

Abstract

Crigler–Najjar Syndrome Type 2 (CNS2) is a rare autosomal recessive disorder characterized by unconjugated hyperbilirubinemia due to partial deficiency of the enzyme uridine diphosphate glucuronosyltransferase 1A1 (UGT1A1). We present a case of a 13-month-old male admitted to Kanti Children’s Hospital with persistent jaundice since birth. Diagnostic evaluation accompanied by gene sequencing confirmed CNS2 and the patient was effectively managed with orally administered phenobarbitone. CNS2 can be distinguished from other potential causes of unconjugated hyperbilirubinemia based on bilirubin concentration and the affected patient’s response to phenobarbitone. Genetic counselling is essential for the recognition and prevention of severe hyperbilirubinemia which, in the absence of timely medical intervention, may lead to neurotoxicity.

Keywords: Case report; crigler-Najjar syndrome; genetic counseling; phenobarbitone; unconjugated hyperbilirubinemia.

Published
2025-06-29
How to Cite
Chand, H., Bhatta, O. P., Chand, S., Dangol, N., Awasthi, S., Poudel, R. C., & Lamichhane, R. P. (2025). Tapentadol withdrawal, a newer trend in opioid overuse in Nepal: A case report. Journal of Nepal Health Research Council, 23(01), 205-207. https://doi.org/10.33314/jnhrc.v23i01.4908